SCHEMBL5463448

SCHEMBL5463448

CCC[C@H](NC(N)=S)c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.44
MEN1 O00255 5/20 0.44
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
FAAH O00519 1/20 0.39
HDAC6 Q9UBN7 1/20 0.38
ATM Q13315 1/20 0.37
METTL3 Q86U44 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465120 0.91 FAAH (0.43) KMT2AMEN1ALDH1A1HPGDFAAH
SCHEMBL5458502 0.83 AOC3 (0.47) KMT2AMEN1ALDH1A1HPGD
SCHEMBL5458535 0.81 LMNA (0.41) KMT2AMEN1ALDH1A1
SCHEMBL5456091 0.79 MAPK1 (0.44) KMT2AMEN1ATM
SCHEMBL5460826 0.79 MAPK1 (0.44) KMT2AMEN1ATM
SCHEMBL5460841 0.79 ESR1 (0.36) KMT2AMEN1ATM
SCHEMBL5462339 0.79 ESR1 (0.36) KMT2AMEN1ATM
SCHEMBL27465380 0.79 ITGB3 (0.30)
SCHEMBL5469855 0.76 PDE2A (0.32) KMT2AMEN1
SCHEMBL27523846 0.75 MEN1 (0.36) KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420679-B2 Aminothiazole derivatives and their use as CRF receptor ligands SANOFI (FR) 2013-04-16 US disclosed
US-20070281919-A1 Aminothiazole Derivatives And Their Use As CRF Receptor Ligands SANOFI-AVENTIS (FR) 2007-12-06 US disclosed
CN-1167692-C Aminothiazole derivatives and their use as CRF receptor ligands ʥŵ��-�ϳ�ʵ���ҹ�˾ 2004-09-22 CN disclosed
US-6586456-B1 Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide SANOFI-SYNTHELABO (FR) 2003-07-01 US disclosed
CN-1370154-A Aminothiazole derivatives and their use as CRF receptor ligands SANOFI SYNTHELABO (FR) 2002-09-18 CN disclosed
EP-1200419-A1 AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS SANOFI-SYNTHELABO (FR) 2002-05-02 EP disclosed
WO-2001005776-A1 AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS SANOFI-SYNTHELABO (FR) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281919-A1 Aminothiazole Derivatives And Their Use As CRF Receptor Ligands CRH, CRHR1, CRHR2 KMT2A 2839/4885MEN1 2126/4885ALDH1A1 4153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.